Nanovibronix (NASDAQ:FEED – Get Free Report) and Vyome (NASDAQ:HIND – Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.
Earnings & Valuation
This table compares Nanovibronix and Vyome”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.69 million | 1.10 | -$3.70 million | ($41.74) | -0.06 |
| Vyome | $8.01 million | 1.94 | -$7.13 million | ($125.20) | -0.02 |
Risk and Volatility
Nanovibronix has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Vyome has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Nanovibronix and Vyome, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Vyome | 1 | 0 | 2 | 0 | 2.33 |
Vyome has a consensus target price of $15.00, indicating a potential upside of 445.45%. Given Vyome’s stronger consensus rating and higher probable upside, analysts clearly believe Vyome is more favorable than Nanovibronix.
Insider and Institutional Ownership
16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Nanovibronix and Vyome’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Vyome | -270.58% | -423.39% | -166.02% |
Summary
Vyome beats Nanovibronix on 9 of the 14 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Vyome
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
